This strategy is currently being tested in several preclinical and clinical trials in other tumors, such as tivantinib in HCC [129], cabozantinib in advanced thyroid cancer [130], and COX-2 inhibitors such as celecoxib, which inhibits the proliferation of CCA cells in vitro [131] and reduces tumor growth in rats with chemically induced CCA [132]. This evidence concerns the gene PTGS2 and hepatocellular carcinoma.